The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

19 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.EBI
Southwest Jiaotong University
Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases.EBI
Southwest Jiaotong University
Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives.EBI
Southwest Jiaotong University
Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements.EBI
Southwest Jiaotong University
Targeting VPS34 in autophagy: An update on pharmacological small-molecule compounds.EBI
Southwest Jiaotong University
Deciphering the multifunctional role of dual leucine zipper kinase (DLK) and its therapeutic potential in disease.EBI
Southwest Jiaotong University
Targeting Death-Associated Protein Kinases for Treatment of Human Diseases: Recent Advances and Future Directions.EBI
Southwest Jiaotong University
Palladium-Catalyzed Synthesis, Acetylcholinesterase Inhibition, and Neuroprotective Activities of EBI
Southwest Jiaotong University
Recent advances of dual FGFR inhibitors as a novel therapy for cancer.EBI
Southwest Jiaotong University
Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors.EBI
Southwest Jiaotong University
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.EBI
Southwest Jiaotong University
Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.EBI
Southwest Jiaotong University
NAE modulators: A potential therapy for gastric carcinoma.EBI
Southwest Jiaotong University
Pd-Catalyzed Direct Diversification of Natural Anti-Alzheimer's Disease Drug: Synthesis and Biological Evaluation of EBI
Southwest Jiaotong University
Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.EBI
Southwest Jiaotong University
Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors.EBI
Southwest Jiaotong University
Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.EBI
Southwest Jiaotong University
Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.EBI
Southwest Jiaotong University
Natural products as important tyrosine kinase inhibitors.EBI
Southwest Jiaotong University